ロード中...
Vorinostat increases carboplatin and paclitaxel activity in non-small cell lung cancer cells
We observed a 53% response rate in non-small cell lung cancer (NSCLC) patients treated with vorinostat plus paclitaxel/carboplatin in a Phase I trial. Studies were undertaken to investigate the mechanism (s) underlying this activity. Growth inhibition was assessed in NSCLC cells by MTT assay after 7...
保存先:
| 主要な著者: | , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
2010
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2795066/ https://ncbi.nlm.nih.gov/pubmed/19621389 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ijc.24759 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|